[
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-1",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#definitiongeneral290787",
    "clean_content": "Definition / general\n\n* Pancreatic ductal adenocarcinoma (PDAC) is an invasive pancreatic epithelial neoplasm with glandular (ductal) differentiation, usually demonstrating luminal or intracellular mucin and without a substantial component of any other histological type"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-2",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#essentialfeatures290788",
    "clean_content": "Essential features\n\n* Adenocarcinoma derived from pancreatic ductal epithelia, with randomly arranged epithelial elements, intense stromal desmoplasia and variable necrosis* Poor prognosis: 5 year survival rate of 6% (ranges from 2 - 9%) ([Cancer Res 2014;74:2913](24840647), [World J Gastroenterol 2016;22:9694](27956793))* Precursors of invasive ductal adenocarcinoma:\n      + [Pancreatic intraepithelial neoplasia (PanIN)](https://www.pathologyoutlines.com/topic/pancreaspanin.html)+ [Intraductal papillary mucinous neoplasm (IPMN)](https://www.pathologyoutlines.com/topic/pancreasipmn.html)+ [Mucinous cystic neoplasm (MCN)](https://www.pathologyoutlines.com/topic/pancreasmcn.html)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-3",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#terminology290789",
    "clean_content": "Terminology\n\n* Sometimes called tubular adenocarcinoma"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-4",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#icdcoding290790",
    "clean_content": "ICD coding\n\n* ICD-11: [2C10.0](https://icd.who.int/browse/2024-01/mms/en#1663659989) - adenocarcinoma of pancreas"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-5",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#epidemiology290791",
    "clean_content": "Epidemiology\n\n* Fourth leading cause of cancer related deaths in the U.S. (predicted to rise to the second most common cause by 2030) ([CA Cancer J Clin 2021;71:7](33433946), [Cancer Res 2014;74:2913](24840647))* Globally, 495,773 new cases and 466,003 new deaths in 2020 ([CA Cancer J Clin 2021;71:209](33538338))* M:F = 1.13:1 ([CA Cancer J Clin 2021;71:209](33538338))"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-6",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#sites290792",
    "clean_content": "Sites\n\n* Head of the pancreas: 60 - 70%; body: 5 - 15%; tail: 10 - 15%* Head tumors: 50% have distention of biliary tree and progressive jaundice; 85% have extension beyond pancreas at diagnosis* Body / tail tumors: typically larger at diagnosis since these tumors do not cause symptoms until late; 25% have peripheral venous thrombi; metastases common* Rarely arises from heterotopic pancreatic tissue in the gastrointestinal tract* Reference: [Surg Pathol Clin 2016;9:547](27926359)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-7",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#pathophysiology290793",
    "clean_content": "Pathophysiology\n\n* Invasive ductal adenocarcinoma arises in association with precursor lesions: PanIN, IPMN or MCN"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-8",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#etiology290794",
    "clean_content": "Etiology\n\n* Risk factors: smoking, alcohol abuse, obesity, high intake of dietary saturated fat, chronic pancreatitis, diabetes* Hereditary syndromes: Peutz-Jeghers syndrome, hereditary pancreatitis, familial atypical multiple mole melanoma (FAMMM), familial pancreatic cancer, Lynch syndrome, familial breast cancer and other Fanconi anemia genes, familial adenomatous polyposis (FAP)* Reference: [World J Gastroenterol 2018;24:4846](30487695)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-9",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#clinicalfeatures290795",
    "clean_content": "Clinical features\n\n* Back pain, weight loss, malaise, jaundice, diabetes mellitus* Trousseau sign: migratory thrombophlebitis in 10% due to tumor or tumor necrosis producing platelet aggregating factors and procoagulants; causes arterial and venous thrombi* Coexisting pancreatitis in 10%* Metastases:\n        + Local lymph nodes (microscopic metastases found in 75% with T1 / T2 disease)+ Liver, lung, peritoneum, adrenal, bone, distal nodes+ Supraclavicular node metastasis may be a presenting symptom+ Tumor may track along biopsy needle path+ Metastases to ovary may simulate primary mucinous ovarian tumors ([Am J Surg Pathol 1989;13:748](2764222))"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-10",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#diagnosis290796",
    "clean_content": "Diagnosis\n\n* Preoperative / pretreatment by endoscopic ultrasound guided fine needle aspiration (EUS-FNA)* Surgical resection specimen"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-11",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#laboratory290797",
    "clean_content": "Laboratory\n\n* Serum tests: CA19-9, CEA"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-12",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#radiologydescription290798",
    "clean_content": "Radiology description\n\n* Hypodense mass on CT imaging in 92% of cases* Double duct sign (dilation of both the biliary and pancreatic ducts) in pancreatic head mass* Reference: [Gastroenterology 2014;146:291](24355035)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-13",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#radiologyimages290799",
    "clean_content": "Radiology images\n\nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/pancreasductalradwiki01.jpg)](https://commons.wikimedia.org/wiki/File:MBq_cystic-carcinoma-pancreas.jpg)\n\nAxial CT pancreas"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-14",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#prognosticfactors290800",
    "clean_content": "Prognostic factors\n\n* Dependent on stage and tumor size* Resectable and size < 4.5 cm are favorable factors* Perineural invasion and vascular invasion are adverse prognostic factors ([Eur J Surg Oncol 2007;33:892](17398060))* High histologic grade unfavorable* Any squamous component indicates poorer prognosis (median survival: 7 - 11 months)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-15",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#casereports290801",
    "clean_content": "Case reports\n\n* Woman in her 50s with faint hypoechoic area in the body of the pancreas ([J Med Ultrason 2018;45:617](29470686))* 63 year old man with lobulated cystic lesion in the head of the pancreas with diffuse dilatation of the main pancreatic duct ([Pancreas 2019;48:e24](30973467))* 78 year old man with two solid tumors in the remnant pancreas after pancreaticoduodenectomy for acinar cell carcinoma ([J Nippon Med Sch 2019;86:279](31061255))"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-16",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#treatment290802",
    "clean_content": "Treatment\n\n* Most (85%) tumors are not amenable to curative surgery* For head / periampullary tumors: Whipple resection (subtotal pancreaticoduodenectomy); perioperative mortality: ~2%* For body / tail tumors: distal pancreatectomy* Resect retroperitoneal nerves and nodes if stage I / II to reduce local recurrence* Palliative treatment: bypass operations, chemotherapy and radiation therapy* Reference: [World J Gastroenterol 2018;24:4846](30487695)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-17",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#grossdescription290803",
    "clean_content": "Gross description\n\n* White gray, sclerotic, poorly defined mass* > 75% are solid tumors* 25% of head tumors extend to duodenal wall* If advanced, may be difficult to determine site of origin between pancreas, ampulla and common bile duct* 20% have multiple tumors* Reference: [Surg Pathol Clin 2016;9:547](27926359)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-18",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#grossimages290804",
    "clean_content": "Gross images\n\n*Contributed by Wei Chen, M.D., Ph.D.*  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChengross01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChengross01.jpg)\n\nArising in IPMN\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChengross02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChengross02.jpg)\n\nArising in high grade PanIN"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-19",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Frozen section description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#frozensectiondescription290805",
    "clean_content": "Frozen section description\n\n* Frozen sections used to confirm diagnosis and determine vascular resectability, margin positivity and status of extraregional lymph nodes / other metastatic sites* Common margins evaluated: pancreatic neck / distal pancreatic parenchyma, bile duct and uncinate* Helpful features of PDAC: anisonucleosis in a single gland (at least 4:1), perineural invasion, tumor gland immediately next to large vessel, single infiltrating cells, low power evaluation for disorganized duct distribution with ill defined borders, necrosis and mitoses ([Arch Pathol Lab Med 2022;146:84](33769446))"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-20",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#microscopichistologicdescription290806",
    "clean_content": "Microscopic (histologic) description\n\n* Infiltrating well to poorly formed glandular / ductal structures surrounded by remarkably desmoplastic stroma* Mucin production is specific for ductal origin versus acinar or neuroendocrine differentiation* Perineural invasion present in 90%, typically with better differentiated glands* Angiolymphatic invasion in 50%; vascular invasion may mimic PanIN ([Am J Surg Pathol 2012;36:235](22082604))* Well differentiated: pink apical band composed of mucin granules, irregular shape and distribution; desmoplasia, marked nuclear pleomorphism with nucleoli, loss of polarity, mitotic figures* Moderately to poorly differentiated (most tumors); abortive tubular structures, deeply infiltrative growth pattern, frequent mitosis, irregular and abortive mucin production* TNM histologic grading system (College of American Pathologists), based on extent of glandular differentiation:\n              + G1 = well differentiated (> 95% tumor composed of glands)+ G2 = moderately differentiated (50 - 95% glands)+ G3 = poorly differentiated (< 50% glands)* Post neoadjuvant therapy ([Hum Pathol 2021;109:1](33245985), [Mod Pathol 2018;31:4](28776577), [Arch Pathol Lab Med 2020;144:838](32023088)):\n                + Variable amount of residual tumor in a densely fibrotic tumor bed+ Attention to perineural space and duodenal wall for residual tumor glands+ Blue-grey fibrosis is a useful clue to suggest the possibility of adjacent residual tumor ([Hum Pathol 2021;109:1](33245985))+ May show vacuolated or eosinophilic tumor cell changes* WHO variants:\n                  + Adenosquamous carcinoma and squamous cell carcinoma+ Colloid carcinoma+ Hepatoid carcinoma+ Medullary carcinoma+ Invasive micropapillary carcinoma+ Signet ring cell (poorly cohesive cell) carcinoma+ Undifferentiated carcinoma (anaplastic, sarcomatoid, carcinosarcoma)+ Undifferentiated carcinoma with osteoclast-like giant cells* Non-WHO variants / patterns:\n                    + Clear cell:\n                      - Glandular, ductal or nested structures with single layer of polygonal cells, distinct cell borders and variable nuclear atypia- Not due to accumulation of glycogen or mucin- Overexpression of HNF1β by IHC ([Mod Pathol 2008;21:1075](18536653))+ Foamy gland:\n                        - Deceptively benign appearing pattern- Well formed glands with bland cells but subtle infiltration- Cells have abundant microvesicular (white and crisply foamy) cytoplasm with distinct pink brush border-like zone at apical / luminal portion of the cell, nuclei are basal oriented, dense or wrinkled (raisinoid)- Foamy material due to evenly sized mucigen granules that are mucin negative- Foamy PanIN proposed to be the precursor lesion ([Am J Surg Pathol 2000;24:493](10757396), [Ann Diagn Pathol 2008;12:252](18620991))+ Large duct:\n                          - Seen in < 10% of PDAC- Clustered ducts with irregular jagged contours (diameter: 0.5 mm - 1 cm)- Desmoplastic and myxoid stroma, intraluminal neutrophils and granular debris- Focal microcystic appearance due to marked ectasia of infiltrating neoplastic glands, particularly near duodenal muscularis propria- May have papillary pattern ([Mod Pathol 2012;25:439](22056954), [Am J Surg Pathol 2012;36:696](22367300))+ Vacuolated:\n                            - High grade tumors, clusters of tumor cells containing large vacuoles imparting cribriform architecture (reminiscent of adipocytes or signet ring cells)- Microcysts contain cellular debris and mucin- Can resemble fat necrosis or lipogranulomas in lymph node- Recognizing the atypical, enlarged, hyperchromatic nuclei is key ([Virchows Arch 2010;457:643](20931225))"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-21",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#microscopichistologicimages290807",
    "clean_content": "Microscopic (histologic) images\n\n*Contributed by Wei Chen, M.D., Ph.D.*  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen001.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen001.jpg)\n\nAnisonucleosis\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen002.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen002.jpg)\n\nGlands next to vessel\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen003.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen003.jpg)\n\nPerineural invasion\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen004.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen004.jpg)\n\nGland in adipose tissue\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen005.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen005.jpg)\n\nModerately differentiated\n\n  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen006.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen006.jpg)\n\nPoorly differentiated\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalChen007.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen007.jpg)\n\nFoamy gland pattern\n\n[![Vacuolated pattern](https://www.pathologyoutlines.com/imgau/pancreasductalChen008.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen008.jpg)\n\nVacuolated pattern\n\n[![Clear cell pattern](https://www.pathologyoutlines.com/imgau/pancreasductalChen009.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen009.jpg)\n\nClear cell pattern\n\n[![Large duct pattern](https://www.pathologyoutlines.com/imgau/pancreasductalChen10.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen10.jpg)\n\nLarge duct pattern\n\n  \n\n[![Post therapy tumor bed](https://www.pathologyoutlines.com/imgau/pancreasductalChen11.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen11.jpg)\n\nPost therapy tumor bed\n\n[![Post therapy eosinophilic change](https://www.pathologyoutlines.com/imgau/pancreasductalChen12.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen12.jpg)\n\nPost therapy eosinophilic change\n\n[![Post therapy dystrophic tumor glands](https://www.pathologyoutlines.com/imgau/pancreasductalChen13.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen13.jpg)\n\nPost therapy dystrophic tumor glands\n\n[![Perineural residual tumor glands](https://www.pathologyoutlines.com/imgau/pancreasductalChen14.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen14.jpg)\n\nPerineural residual tumor glands\n\n[![Post therapy vascular change](https://www.pathologyoutlines.com/imgau/pancreasductalChen15.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalChen15.jpg)\n\nPost therapy vascular change"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-22",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Virtual slides",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#virtualslides290808",
    "clean_content": "Virtual slides\n\nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/pancreasductalTor01.jpg)](http://dlm.lmp.utoronto.ca/image/pancreas-ductal-adenocarcinoma-lmp67240)\n\nPancreatic ductal adenocarcinoma"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-23",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#cytologydescription290809",
    "clean_content": "Cytology description\n\n* EUS-FNA has sensitivity and specificity of > 90% and 100%, increased sensitivity with ThinPrep, brushings are 50% sensitive (repeat if inconsistent with clinical or radiologic findings) ([Arch Pathol Lab Med 2000;124:387](10705391))* Aspirates are cellular, without acinar cells, with atypical ductal cells in sheets (drunken honeycomb), clusters or singly; anisonucleosis (4:1 variation)* Signet ring cells and mitotic figures are helpful when present* Papanicolaou Society of Cytopathology's 6 tiered system for pancreatobiliary cytology: nondiagnostic, negative for malignancy, atypical, neoplastic, suspicious and positive / malignant ([Cytojournal 2014;11:3](25191517))* Duodenal secretions are 80% sensitive in head tumors, 33% sensitive in tail tumors; endoscopic retrograde cholangiopancreatography (ERCP) juice is 50 - 85% sensitive"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-24",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#cytologyimages290810",
    "clean_content": "Cytology images\n\nContributed by Regina Plummer, D.O., Victoria Saksenberg, M.D. and AFIP images  \n\n[![Abundant inspissated mucin](https://www.pathologyoutlines.com/imgau/pancreasductalplummer03.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalplummer03.jpg)\n\nAbundant inspissated mucin\n\n[![Transition into drunken honeycomb](https://www.pathologyoutlines.com/imgau/pancreasductalplummer01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalplummer01.jpg)\n\nTransition into drunken honeycomb\n\n[![Anisonucleosis (4:1 variation)](https://www.pathologyoutlines.com/imgau/pancreasductalplummer02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalplummer02.jpg)\n\nAnisonucleosis (4:1 variation)\n\n[![Signet ring cells](https://www.pathologyoutlines.com/imgau/pancreasductalSaksenberg01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalSaksenberg01.jpg)\n \n[![Signet ring cells](https://www.pathologyoutlines.com/imgau/pancreasductalSaksenberg02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalSaksenberg02.jpg)\n\nSignet ring cells\n\n[![Missing Image](https://www.pathologyoutlines.com/images/pancreas/9_03.jpg)](https://www.pathologyoutlines.com/images/pancreas/9_03.jpg)\n\nModerately   \ndifferentiated   \nductal   \nadenocarcinoma"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-25",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#positivestains290811",
    "clean_content": "Positive stains\n\n* **Maspin**, [placental S100 (S100P)](https://www.pathologyoutlines.com/topic/stainss100p.html), [IMP3](https://www.pathologyoutlines.com/topic/stainsIMP3.html) (all positive in > 90% PDACs) ([Arch Pathol Lab Med 2012;136:601](22646265), [Hum Pathol 2013;44:503](23079206))* [p53](https://www.pathologyoutlines.com/topic/stainsp53.html)\n    expressed in most cases* [CK7](https://www.pathologyoutlines.com/topic/stainsck7.html),\n      [CK8](https://www.pathologyoutlines.com/topic/stainsck8.html),\n      [CK18](https://www.pathologyoutlines.com/topic/stainsck18.html),\n      [CK19](https://www.pathologyoutlines.com/topic/stainsck19.html),\n      [MUC1](https://www.pathologyoutlines.com/topic/stainsema.html),\n      [MUC3](https://www.pathologyoutlines.com/topic/stainsmuc2.html),\n      [MUC4](https://www.pathologyoutlines.com/topic/stainsmuc2.html),\n      [MUC5AC](https://www.pathologyoutlines.com/topic/stainsmuc2.html),\n      [CEA](https://www.pathologyoutlines.com/topic/stainscea.html),\n      [B72.3](https://www.pathologyoutlines.com/topic/stainsb723.html),\n      [CA19-9](https://www.pathologyoutlines.com/topic/stainsca19-9.html),\n      [CA125](https://www.pathologyoutlines.com/topic/stainsCA125.html) (48%)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-26",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#negativestains290812",
    "clean_content": "Negative stains\n\n* [pVHL](https://www.pathologyoutlines.com/topic/stainsvhl.html) negative / loss seen in > 90% PDACs ([Arch Pathol Lab Med 2012;136:601](22646265), [Hum Pathol 2013;44:503](23079206))* Loss of [SMAD4 / DPC4](https://www.pathologyoutlines.com/topic/stainsdpc4.html) seen in 55%; specific for malignancy (in situ or invasive) ([Am J Clin Pathol 2001;116:831](11764071))* [CK20](https://www.pathologyoutlines.com/topic/stainsck20.html),\n      [MUC2](https://www.pathologyoutlines.com/topic/stainsmuc2.html),\n      [vimentin](https://www.pathologyoutlines.com/topic/stainsvimentin.html),\n      [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html),\n      [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html),\n      [trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html),\n      **chymotrypsin**, **lipase**"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-27",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Electron microscopy description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#electronmicroscopydescription290813",
    "clean_content": "Electron microscopy description\n\n* Mucigen granules"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-28",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Electron microscopy images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#electronmicroscopyimages290814",
    "clean_content": "Electron microscopy images\n\nAFIP images  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreasductalEMIAFIP1.jpg)](https://www.pathologyoutlines.com/imgau/pancreasductalEMIAFIP1.jpg)\n\nWell differentiated"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-29",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#molecularcytogeneticsdescription290815",
    "clean_content": "Molecular / cytogenetics description\n\n* 4 key driver gene mutations ([Arch Pathol Lab Med 2011;135:716](21631264), [Hum Pathol 2009;40:612](19362631), [Cancer Cell 2017;32:185](28810144))\n  + *KRAS*: > 95%, early event during carcinogenesis ([Cancer 2007;109:1561](17354229))+ *CDKN2A* (p16): 95%+ *TP53*: 50 - 80%+ *SMAD4*: 55%* 50% overexpress HER2* Many core signaling pathways involved* ~10% of pancreatic cancers have a familial basis"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-30",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#samplepathologyreport290816",
    "clean_content": "Sample pathology report\n\n* Distal stomach, duodenum and pancreatic head, pancreaticoduodenectomy:\n  + Moderately differentiated pancreatic ductal adenocarcinoma, 2.2 cm+ Adenocarcinoma involves distal bile duct+ All margins negative for carcinoma or high grade dysplasia+ Positive for lymphovascular invasion and perineural invasion+ Metastatic adenocarcinoma involving 2 of 23 lymph nodes (2/23)+ Portion of benign stomach with chronic inactive gastritis, negative for *Helicobacter pylori* on H&E+ Benign duodenum with no significant pathologic change"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-31",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#differentialdiagnosis290817",
    "clean_content": "Differential diagnosis\n\n* [Ampullary adenocarcinoma](https://www.pathologyoutlines.com/topic/ampullaadenocarcinoma.html):\n  + Epicenter at ampulla, presence of preinvasive component at ampulla* [Chronic pancreatitis](https://www.pathologyoutlines.com/topic/pancreaschronic.html):\n    + Lobular architecture at low power with central ectatic branched ductules and clusters of round ductules surrounded by cuff of stroma ([Arch Pathol Lab Med 2009;133:382](19260744))+ Features of PDAC to differentiate from chronic pancreatitis ([Arch Pathol Lab Med 2015;139:848](26125425)):\n        - Haphazard architecture and glands at abnormal locations in interlobular areas, next to vessels and naked glands in fat- Anisonucleosis (4:1 variation), loss of cell polarity, perineurial invasion, individual cell infiltration, budding into lumen; has [p53](https://www.pathologyoutlines.com/topic/stainsp53.html) mutations and loss of *SMAD4* / *DPC4** [Distal bile duct adenocarcinoma](https://pathologyoutlines.com/topic/gallbladdercarcinomaextrahepatic.html):\n      + Epicenter at bile duct, circumferential / symmetrical involvement of the bile duct, presence of in situ component (BilIN or biliary intraductal papillary neoplasm)"
  },
  {
    "id": "ductal-adenocarcinoma-nos_37818_1750166973.txt-32",
    "source_document": "ductal-adenocarcinoma-nos_37818_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/pancreasductal.html#additionalreferences290818",
    "clean_content": "Additional references\n\n* [WHO Classification of Tumours Editorial Board: Digestive System Tumours (Medicine), 5th Edition, 2019](https://www.amazon.com/exec/obidos/ASIN/9283244990/pathologyoutl-20),\n  [Semin Diagn Pathol 2014;31:443](25441308),\n  [Arch Pathol Lab Med 2017;141:366](28055239)"
  }
]